Navigation Links
NeurogesX CEO Anthony DiTonno to Retire by Year End
Date:4/29/2011

SAN MATEO, Calif., April 29, 2011 /PRNewswire/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that long time CEO Anthony DiTonno will retire by December 31, 2011. The Board of Directors has initiated a formal executive search for a Chief Executive Officer.

Anthony DiTonno commented, "I have been CEO of NeurogesX for more than eight years and we have accomplished the objectives I established for myself when I joined the Company in March 2003. It has been my privilege to work with my colleagues at NeurogesX to take Qutenza through all phases of clinical development and regulatory approvals throughout the world resulting in the successful launch of Qutenza in the United States by our sales team and with our partner Astellas in Europe, the Middle East and Africa. Our focus on finding a replacement will be to find someone with the appropriate commercial and business experience to take the Company to the next level. As we enter our second full year of commercialization, the timing is ideal for this transition to lead this great company into the future. Decisions like this are difficult and I cannot overstate my enthusiasm for Qutenza and NeurogesX going forward."

Jean-Jacques Bienaime commented, "The Board of Directors thanks Tony for his vision, leadership and tenacity during his tenure as CEO. We are pleased that he has agreed to continue to lead the Company up to the end of the year to assure a smooth transition of leadership."

Mr. Bienaime continued, "At the same time, we are excited to have Gary Lyons join our board. Gary has extensive biotech experience and demonstrated success in commercial, business development and financing, which I believe will benefit the Company greatly."

Gary A. Lyons served as a director of Neurocrine Biosciences since Febru
'/>"/>

SOURCE NeurogesX
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeurogesX to Pursue Expanded U.S. Label for Qutenza® (capsaicin) 8% Patch in HIV-Associated Neuropathy
2. NeurogesX to Present at J.P. Morgan Health Care Conference
3. NeurogesX to Present at Piper Jaffray Health Care Conference
4. NeurogesX Reports Third Quarter 2009 Results
5. NeurogesX to Present at Two November Conferences
6. NeurogesX to Present at UBS Global Life Sciences Conference
7. NeurogesX to Present at Upcoming Fall Conferences
8. NeurogesX Appoints New Board Director and Audit Committee Chairman
9. NeurogesX Reports Second Quarter 2009 Results
10. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
11. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... A new study by researchers from the University ... tiny nanosystems function, unlocking the potential to create ... study, which has been published in the prestigious ... a novel laser technique to examine in rich ... a small cluster containing an acetylene molecule and ...
(Date:7/25/2014)... Albany, New York (PRWEB) July 25, 2014 ... Transparency Market Research, "Biological Drugs Market - Global Industry ... 2020," the global biological drugs market is estimated at ... grow at a CAGR of 10.1% from 2014 to ... million in 2020. , The biological drugs market is ...
(Date:7/25/2014)... The Conferee Networking committee is pleased to announce ... two-hour sessions provide a unique networking opportunity for attendees ... new techniques, or brainstorm new ideas in an informal ... consideration is August 31, 2014, and instructions can be ... will review the topics, and status notifications will be ...
(Date:7/25/2014)... 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... the development and commercialization of a once-daily, oral therapy ... today announced financial results for the period ended June ... , Reported cash and cash equivalents totaling $37.4 ... December 31, 2013.  , Reported a net loss ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6
... ThermoGenesis,Corp. (Nasdaq: KOOL ), a leading supplier of ... therapeutic doses of,adult stem cells for treatment of disease ... the fiscal first quarter ended September,30, 2007, on Thursday, ... Management will host a conference call Thursday, November ...
... Motorization Meets ... MELVILLE, N.Y., Nov. 1 Nikon Instruments, Inc., ... more than twice that of previous Nikon inverted ... research microscope. The Ti-E,offers advanced functionality, which now ...
... ... Third Quarter EPS of $0.70 per Basic Share, or $0.66 per Diluted Share, - Third Quarter ... ... Corporation (Nasdaq: UTHR ) today announced its results of,operations for the quarter ended September 30, 2007. ...
Cached Biology Technology:ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007 2ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007 3Nikon Instruments Launches New Eclipse Ti-E Fully-Integrated, Motorized Inverted Microscope 2Nikon Instruments Launches New Eclipse Ti-E Fully-Integrated, Motorized Inverted Microscope 3United Therapeutics Reports Third Quarter 2007 Financial Results 2United Therapeutics Reports Third Quarter 2007 Financial Results 3United Therapeutics Reports Third Quarter 2007 Financial Results 4United Therapeutics Reports Third Quarter 2007 Financial Results 5United Therapeutics Reports Third Quarter 2007 Financial Results 6United Therapeutics Reports Third Quarter 2007 Financial Results 7United Therapeutics Reports Third Quarter 2007 Financial Results 8United Therapeutics Reports Third Quarter 2007 Financial Results 9
(Date:7/28/2014)... many of these due to genetic factors. This is ... which reduce an individual,s ability to reproduce, to disappear ... Science that recently appeared in Nature Communications ... it explain the high rates of male fertility problems, ... of genetic diseases and their treatment. , Various ...
(Date:7/27/2014)... the asteroid strike that wiped them out if it ... scientists say. , A fresh study using up-to-date fossil ... build a new narrative of the prehistoric creatures, demise, ... in the few million years before a 10km-wide asteroid ... upheaval. This included extensive volcanic activity, changing sea levels ...
(Date:7/27/2014)... Cancer Institute have found that targeting a molecule in ... according to research published in Nature today ... Queen Mary University of London, have found that a ... to repair itself after chemotherapy or radiotherapy, which kill ... FAK from blood vessels that grew in melanoma or ...
Breaking Biology News(10 mins):Mutations from Venus, mutations from Mars 2Dinosaurs fell victim to perfect storm of events, study shows 2New drug target can break down cancer's barrier against treatment 2
... HawaiiA team of scientists from the USDA Forest ... universities will begin research using sophisticated topographic models ... the most potential for ecological restoration. ... PSW research ecologist; Dr. Erin Questad, assistant professor, ...
... Sotillo, a staff scientist at the European Molecular Biology ... young biomedical scientists who have been honoured with a ... award this year. The prize, $650,000 for five years, ... working in selected countries outside the United States. The ...
... REDWOOD CITY, Calif., Jan. 24, 2012 Ingenuity ... solutions for life science researchers, today announced the ... that provides the fastest way to get biological ... integrated, one-step solution for the statistical analysis and ...
Cached Biology News:High-tech models help guide restoration efforts to save threatened plants 2Ingenuity Systems iReport Now Available: Fast, Accurate, Interactive Report for Gene Expression Data 2
... MAP1 Light Chain MAP1A and MAP1B are ... microtubules and components of the cytoskeleton. MAP1A and ... and multiple light chain subunits. The protein encoded ... chain subunits and can associate with either MAP1A ...
PC based system for advanced chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
Biology Products: